NewsBenzingaKeefe, Bruyette & Woods mantiene il giudizio “Underperform” su Allstate, alza il target price a 241 dollari Keefe, Bruyette & Woods mantiene il giudizio “Underperform” su Allstate, alza il target price a 241 dollari Benzinga 2026.11.10 12:18 (GMT+0) Open on Benzinga Other news Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14 Needham Maintains Buy on DocGo, Lowers Price Target to $1 Needham Maintains Buy on Nerdy, Raises Price Target to $8 FDA Flags Potential Vision Loss Risk With GLP-1 Drugs, Requiring Weight-Loss Medicines Like Wegovy and Zepbound to Carry New Warning Atossa Therapeutics Q3 EPS $(0.56) Beats $(0.90) Estimate Mobix Labs Gives Preliminary Q4 Revenue Of $1.81M, Up From $789K YoY
FDA Flags Potential Vision Loss Risk With GLP-1 Drugs, Requiring Weight-Loss Medicines Like Wegovy and Zepbound to Carry New Warning
